Marijuana Company of America Inc. Expands hempSMART™ Product Line with New Pet Product | CashCropToday
0 Shares 306 Views

Marijuana Company of America Inc. Expands hempSMART™ Product Line with New Pet Product

March 24, 2018
306 Views
  • MCOA launches new CBD-based natural pet product – hempSMART™ Full Spectrum Pet Drops
  • Targets hottest sector of booming pet care industry
  • Product dovetails with consumer interest and affiliate sales

Marijuana Company of America Inc. (OTC: MCOA), a leader in the production of high quality CBD products derived solely from industrial hemp, just announced the release of a new product designed for pets. Nearly $67 billion was spent on pets in the U.S. in 2017, and MCOA’s new pet supplement targets the hottest sector of the booming pet care market – natural pet supplements.

Natural pet products are gaining widespread popularity, because consumers are more aware of the toxicity of certain synthetic chemicals and other harmful materials. Consequently, pet owners are increasingly choosing to purchase natural products in an effort to maintain and improve the health and well-being of their beloved companion animals (http://cnw.fm/S37vP).

MCOA’s hempSMART™ Full Spectrum Pet Drops for cats and dogs are formulated with 250mg of full spectrum non-psychoactive cannabidiol (CBD) derived from industrial hemp. The new, specially-formulated product contains naturally-occurring CBD derived from hemp seed oil, full spectrum hemp extract, fractionated coconut oil and a rich bacon flavor that pets will love. The new Full Spectrum Pet Drops add a new vertical to MCOA’s fast growing hempSMART™ product line and are expected to garner strong interest from pet owners.

Commenting on the new pet product in a news release, Donald Steinberg, MCOA’s CEO, stated, “Our new hempSMART product is a natural option for pet owners who care about supporting their animals’ healthy energy levels as well as optimizing their health. Our hempSMART product line will continue to expand to other popular areas of consumer interest to give our affiliates what they need to succeed.”

hempSMART’s multidimensional approach to CBD-based consumer products is bolstered by its unique distribution plan of turning product users into passionate product promoters. hempSMART employs an affiliate marketing program to promote and sell its industrial hemp-based consumer CBD products. As more and more people use and realize benefits from the products, more of them sign on to introduce the products to friends and neighbors. The affiliate program continues to gain traction and is expected to significantly impact revenues while keeping costs in check. MCOA’s new hempSMART™ Full Spectrum Pet Drops dovetail perfectly with consumer demand and the affiliate sales model. Given consumer interest and their love for pets, it wouldn’t be a surprise if hempSMART’s pet drops far exceed expectations.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
270 views
Market Watch
270 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: